International Journal of Clinical Pharmacy

, Volume 36, Issue 5, pp 896–903 | Cite as

Effectiveness of pharmacist intervention in patients with chronic kidney disease

  • Aurelio Cabello-MurielEmail author
  • Juan José Gascón–Cánovas
  • Elena Urbieta-Sanz
  • Carles Iniesta-Navalón
Research Article


Background Collaboration between pharmacists and physicians in the care of patients with chronic kidney disease (CKD) may improve the quality of drug dosage regimens that require adjustment according to the renal function. Objective To demonstrate that the intervention of a pharmacist in a monitoring program for patients with CKD improves the outcome of renal function in these patients. Setting A 330-bed regional referral hospital in the city of Murcia (Spain). Method All patients with CKD and taking nephrotoxic medication admitted to the internal medicine service were included in the study. Depending on the department of the hospital to which the patients were admitted, they were assigned to an intervention or control group. In the control group, the renal function at the time of admission and discharge was measured. In the intervention group, in addition to measuring kidney function at the time of admission and at discharge, the patients were followed daily and recommendation for dose adjustment were made when nephrotoxic drugs were not properly dosed. Main outcome measure Glomerular filtration rate on admission and at discharge. Results A total of 249 patients were included in the study, 124 in the control group and 125 in the intervention group. Significant differences were noted when comparing creatinine clearance (CrCl) between discharge and admission in both the control and intervention groups (5.1 ± 0.9 vs. 6.4 ± 1.0 p < 0.01). In a comparison of the observed improvement in the two groups, we found significant differences in adjusted relative CrCl according to sex, age and stage (19.9 [1.2–38.5] p < 0.05). When the disease was analyzed by stage, we observed significant differences that favored the intervention group in regards CrCl (3.1 ± 2.1 vs. 7.9 ± 3.8 p < 0.05) and relative CrCl (16.1 ± 10.3 vs. 36.6 ± 16.7) in stages 4–5. The rate of acceptance of the pharmacists’ recommendations was 74 %. Conclusion The implementation of a monitoring program for CKD patients was effective in the group in which monitoring was conducted, especially in patients with more advanced stage of CKD.


Chronic kidney disease Dose adjustment Hospitalized patients Internal medicine department Nephrotoxic drugs Pharmacist intervention Renal function Spain 



This study is possible due to the invaluable collaboration of the medical and nursing teams of Internal Medicine Department of the Hospital Reina Sofia of Murcia.


This study had no specific source of funding.

Supplementary material

11096_2014_1_MOESM1_ESM.pdf (186 kb)
Supplementary material 1 (PDF 186 kb)


  1. 1.
    Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adults US population: Third Natinonal Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Otero A, de Francisco ALM, Gayoso P, García F, et al. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología. 2010;30:78–86.PubMedGoogle Scholar
  4. 4.
    Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Alvarez L, Climent E, Bosacoma N, Roca S, Perdiguero M, Ordovás JP, et al. Evaluación de un programa de intervención farmacéutica en pacientes con medicamentos de riesgo renal [Evaluation of a pharmaceutical intervention program in patients with renal risk drugs]. Farm Hosp. 2009;33:147–54 Spanish.CrossRefGoogle Scholar
  6. 6.
    Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–15.PubMedCrossRefGoogle Scholar
  7. 7.
    Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function-an understaimated problem? Nephrol Dial Transplant. 2006;21:3164–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Fabregas X, Agustí C, Gurrera T, Felip A. Evaluación de la intervención farmacéutica en un programa de reajuste de dosis en pacientes con función renal alterada [Evaluation of pharmaceutical intervention in a dose adjustment program in patients with impaired renal function]. Farm Hosp. 2003;27(Supl 1):28. Spanish.Google Scholar
  9. 9.
    Falconnier AD, Haeffeli WE, Schonenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by inmediate concurrent feedback. J Gen Intern Med. 2001;16:369–75.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Lavilla FJ, Ferrer A. Fracaso renal agudo: clasificación, etiopatogenia y factores pronósticos [Acute renal failure: classification, pathogenesis and prognostic factors]. Medicine. 2011;10:5348–55 Spanish.Google Scholar
  11. 11.
    Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Sweileh WM, Janem SA, Sawalha AF, Abu-Taha AS, Zyoud SH, Sabri IA, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf. 2007;16:908–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Salomon L, Deray G, Jaundon MC, Chebaiser C, Bossi P, Launay-Vacher V, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care. 2003;15:331–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacist´s interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2011;0:1–17.Google Scholar
  15. 15.
    Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29:1433–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Leung WY, So WY, Tong PC, et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118:1414.PubMedCrossRefGoogle Scholar
  17. 17.
    Bucaloiu ID, Akers G, Bermudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20:26–30.PubMedGoogle Scholar
  18. 18.
    Yokum D, Glass G, Cheung CF, et al. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr. 2008;18:521–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis. 2008;15:162–7.PubMedCrossRefGoogle Scholar
  20. 20.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.Google Scholar
  21. 21.
    Grupo de trabajo de Farmacia y Nefrología. Guía de dosificación de fármacos en insuficiencia renal. HGU Reina Sofía Murcia [Guide to drug dosage in renal failure. HGU Reina Sofia Murcia].2012.Unidad Técnica de Comunicación. Spanish.Google Scholar
  22. 22.
    Mensa J, Gatell JM, Garcia-Sanchez JE, Letang E, Lopez-Suñe E, Marco F. Guía de terapéutica antimicrobiana [Guide antimicrobial therapy] 2011. Ed Antares. 2011.Spanish.Google Scholar
  23. 23.
    Fichas técnicas de los medicamentos. Agencia Española de Medicamentos y Productos Sanitarios. [Last cited 6- 2012].
  24. 24.
    David N, Robert C, George M, Henry F, Michael S, The Sanford guide to Antimicrobial Therapy 2011. Forty-first edition. 2011.Google Scholar
  25. 25.
    Machin D, Campbell M, Fayers P, Pinol A. Sample size tables for clinical studies. 2nd ed. Blackwell Science; 1997.Google Scholar
  26. 26.
    Devesa C, Matoses C, Peral L, Sanz G, Murcia AC, Navarro A. Atención farmacéutica en pacientes ingresados con insuficiencia renal [Pharmaceutical care in patients hospitalized with kidney failure]. Farm Hosp. 2012;36:483–91 Spanish.Google Scholar
  27. 27.
    Montañés-Paul B, Sáez-Lleó C, Martínez-Romero G. Ajuste de dosificación de medicamentos en pacientes ancianos institucionalizados con insuficiencia renal [Adjust dosage of drugs in institutionalized elderly patients with renal insufficiency]. Farm Hosp. 2009;33:43–7 Spanish.CrossRefGoogle Scholar
  28. 28.
    Nyman H, Dowling T, Hudson J, Peter W, Joy M, Nolin T, et al. Comparative evaluation of the Cockcroft-Gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing. Pharmacotherapy. 2011;31:1130–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Stevens L, Nolin T, Richardson M, Feldman H, Lewis J, Rodby R, et al. Comparasion of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney. 2009;54:33–42.CrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Aurelio Cabello-Muriel
    • 1
    Email author
  • Juan José Gascón–Cánovas
    • 2
  • Elena Urbieta-Sanz
    • 1
  • Carles Iniesta-Navalón
    • 1
  1. 1.Pharmacy departmentHospital General Universitario Reina Sofía of MurciaMurciaSpain
  2. 2.Public-health sciences departmentUniversity of MurciaMurciaSpain

Personalised recommendations